Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EPS (Weighted Average and Diluted) (2022 - 2025)

Autolus Therapeutics (AUTL) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.3 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 3.23% year-over-year to -$0.3, compared with a TTM value of -$0.83 through Sep 2025, up 31.97%, and an annual FY2024 reading of -$0.86, up 28.33% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.3 for Q3 2025 at Autolus Therapeutics, down from -$0.18 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.09 in Q4 2024 and bottomed at -$0.47 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.28, with a median of -$0.26 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 95.65% in 2023, then skyrocketed 80.0% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.23 in 2022, then plummeted by 95.65% to -$0.45 in 2023, then surged by 80.0% to -$0.09 in 2024, then tumbled by 233.33% to -$0.3 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AUTL at -$0.3 in Q3 2025, -$0.18 in Q2 2025, and -$0.26 in Q1 2025.